Uncertainty Regarding the Prolonged Development Pipeline, Discontinuation and Commercialization
First written in FY2023. 2 of 3 entries say "Restated". Latest entry: FY2025.
The whole theme swung hardest in 2022: 20 of 40 companies on the "Worse" side.
28 other companies' latest entry also says "Restated".
- FY2025RestatedAnnual report
「There is a risk that research and development will not progress as planned, requiring the development period to be extended or development to be discontinued.」
The company reiterates the risk of delays, discontinuation or abandonment of commercialization because of clinical trials, data evaluation, regulatory approval and other factors. - FY2024RestatedAnnual report
「There is a risk that research and development will not progress as planned, requiring the development period to be extended or development to be discontinued.」
The company reiterates the risk of delays, discontinuation or abandonment of commercialization because of clinical trials, data evaluation, regulatory approval and other factors. - FY2023First statedAnnual report
「Research and development may fail to progress as planned because of delays in enrolling patients in clinical trials or an inability to confirm useful effects, and it is not uncommon to extend the research and development period or decide to discontinue development.」
The company identifies the risk that pipelines may not reach commercialization because of clinical-trial delays, insufficient efficacy or delays in obtaining approval.